Skip to main content

Progress in Medicinal Chemistry

  • 1st Edition, Volume 61 - June 17, 2022
  • Latest edition
  • Editors: David R. Witty, Brian Cox
  • Language: English

Progress in Medicinal Chemistry, Volume 61 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of author… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Description

Progress in Medicinal Chemistry, Volume 61 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors.

Key features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs

Readership

Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes

Table of contents

Contributors in this volume include:
Kat Van Rietschoten
Karthik Iyer
Rick Cousins
Werngard Czechitzky
Charlotte Hardy

Product details

  • Edition: 1
  • Latest edition
  • Volume: 61
  • Published: June 17, 2022
  • Language: English

About the editors

DW

David R. Witty

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and expertise
WITNET LTD, Cambridge, UK

BC

Brian Cox

Professor Brian Cox is at University of Sussex, Brighton, UK
Affiliations and expertise
Professor, University of Sussex, Brighton, UK

View book on ScienceDirect

Read Progress in Medicinal Chemistry on ScienceDirect